← Back to Search

CAR T-cell Therapy

Evaluation of the Safety and Efficacy of ASCA101 in Patients With Advanced Solid Tumors

Phase 1
Waitlist Available
Research Sponsored by MetaFines
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023]
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new treatment in patients whose previous treatments did not work. The goal is to find out how safe and effective the new treatment is.

Eligible Conditions
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023]
This trial's timeline: 3 weeks for screening, Varies for treatment, and from first dose until documented disease progression or death, up to 36 months or until database cutoff date of 14jul2023] for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Maximum tolerated dose(MTD)
Secondary study objectives
Duration of Response(DoR)
Objective response rate(ORR)
Progression Free Survival(PFS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: ASCA101 IVExperimental Treatment1 Intervention
The study drug, ASCA101(300mg/vial), will be reconstituted in water for injection and diluted with saline to a dose calculated according to individual body surface area or body weight.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ASCA101
2021
Completed Phase 1
~20

Find a Location

Who is running the clinical trial?

MetaFinesLead Sponsor

Media Library

ASCA101 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05547906 — Phase 1
Solid Tumors Research Study Groups: ASCA101 IV
Solid Tumors Clinical Trial 2023: ASCA101 Highlights & Side Effects. Trial Name: NCT05547906 — Phase 1
ASCA101 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05547906 — Phase 1
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top